(Total Views: 510)
Posted On: 10/08/2024 9:26:19 PM
Post# of 154155
Dr. J/ Dr. L & BMS --
HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced
Subjects: Week 24 Analysis
AI438011:
A Phase IIb, Randomized, Controlled, Partially-Blinded Trial to Investigate the Safety, Efficacy and Dose-response of BMS-663068 in
Treatment-Experienced HIV-1-positive Subjects
Lalezari J, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, and Lataillade M for the AI438011 study team
Financial Disclosures:
This study was funded by Bristol-Myers Squibb
____
That is from April 2014 pdf:
Third Conference of the British HIV Association
Dr. J said today that he's collaborated with Dr. Lataillade for 10 yrs.
HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced
Subjects: Week 24 Analysis
AI438011:
A Phase IIb, Randomized, Controlled, Partially-Blinded Trial to Investigate the Safety, Efficacy and Dose-response of BMS-663068 in
Treatment-Experienced HIV-1-positive Subjects
Lalezari J, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, and Lataillade M for the AI438011 study team
Financial Disclosures:
This study was funded by Bristol-Myers Squibb
____
That is from April 2014 pdf:
Third Conference of the British HIV Association
Dr. J said today that he's collaborated with Dr. Lataillade for 10 yrs.
(4)
(0)
